相似文献
1
The Role of Health Economics and Outcomes Research in Addressing Coronavirus Disease 2019 (COVID-19).
Value Health. 2020 Nov;23(11):1403-1404. doi: 10.1016/j.jval.2020.09.009. Epub 2020 Oct 13.
2
Beyond COVID-19: How the 'dismal science' can prepare us for the future.
Health Econ. 2020 Aug;29(8):851-853. doi: 10.1002/hec.4114. Epub 2020 Jun 2.
3
Clinical features of 95 sequential hospitalised patients with novel coronavirus 2019 disease (COVID-19), the first UK cohort.
J Infect. 2020 Aug;81(2):e59-e61. doi: 10.1016/j.jinf.2020.04.020. Epub 2020 Apr 27.
4
Primary care networks: the impact of covid-19 and the challenges ahead.
BMJ. 2020 Sep 3;370:m3353. doi: 10.1136/bmj.m3353.
5
Updated rapid risk assessment from ECDC on coronavirus disease (COVID-19) pandemic in the EU/EEA and the UK: resurgence of cases.
Euro Surveill. 2020 Aug;25(32). doi: 10.2807/1560-7917.ES.2020.25.32.2008131.
6
COVID-19 and medical education.
Lancet Infect Dis. 2020 Jul;20(7):777-778. doi: 10.1016/S1473-3099(20)30226-7. Epub 2020 Mar 23.
7
Covid-19: how a virus is turning the world upside down.
BMJ. 2020 Apr 3;369:m1336. doi: 10.1136/bmj.m1336.
8
Political casualties of the COVID-19 pandemic.
Lancet Infect Dis. 2020 Jul;20(7):755. doi: 10.1016/S1473-3099(20)30496-5. Epub 2020 Jun 11.
9
COVID-19, a UK perspective.
Eur J Emerg Med. 2020 Jun;27(3):156-157. doi: 10.1097/MEJ.0000000000000700.
10
COVID-19: an opportune period to reform the medical curriculum.
J R Coll Physicians Edinb. 2020 Sep;50(3):343-350. doi: 10.4997/JRCPE.2020.328.
引用本文的文献
1
Cost-Effectiveness of COVID-19 Policy Measures: A Systematic Review.
Value Health. 2021 Nov;24(11):1551-1569. doi: 10.1016/j.jval.2021.05.013. Epub 2021 Sep 30.
2
Health Economics of Interventions to Tackle the Coronavirus 2019 Pandemic.
Value Health. 2021 May;24(5):605-606. doi: 10.1016/j.jval.2021.03.002. Epub 2021 Apr 16.
本文引用的文献
1
Willingness to Accept Trade-Offs Among COVID-19 Cases, Social-Distancing Restrictions, and Economic Impact: A Nationwide US Study.
Value Health. 2020 Nov;23(11):1438-1443. doi: 10.1016/j.jval.2020.07.003. Epub 2020 Sep 4.
2
Costing the COVID-19 Pandemic: An Exploratory Economic Evaluation of Hypothetical Suppression Policy in the United Kingdom.
Value Health. 2020 Nov;23(11):1432-1437. doi: 10.1016/j.jval.2020.07.001. Epub 2020 Aug 27.
3
The Economic and Public Health Imperatives Around Making Potential Coronavirus Disease-2019 Treatments Available and Affordable.
Value Health. 2020 Nov;23(11):1427-1431. doi: 10.1016/j.jval.2020.04.1824. Epub 2020 May 21.
4
Coronavirus Disease 2019: Considerations for Health Technology Assessment From the National Centre for Pharmacoeconomics Review Group.
Value Health. 2020 Nov;23(11):1423-1426. doi: 10.1016/j.jval.2020.09.003. Epub 2020 Oct 5.
5
Cost-Effectiveness of Antiviral Treatments for Pandemics and Outbreaks of Respiratory Illnesses, Including COVID-19: A Systematic Review of Published Economic Evaluations.
Value Health. 2020 Nov;23(11):1409-1422. doi: 10.1016/j.jval.2020.07.002. Epub 2020 Sep 6.
6
Measuring "Fearonomic Effects" in Valuing Therapies: An Application to COVID-19 in China.
Value Health. 2020 Nov;23(11):1405-1408. doi: 10.1016/j.jval.2020.06.002. Epub 2020 Jul 27.
Zotero 插件